FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085764274> ?p ?o ?g. }

• W2085764274 endingPage "134" @default.
• W2085764274 startingPage "124" @default.
• W2085764274 abstract "Arthritis & RheumatismVolume 11, Issue 2 p. 124-134 Review ArticleFree to Read The prevention and treatment of osteoporosis Brian D. Golden MD, Corresponding Author Brian D. Golden MD Co-Director, Osteoporosis Center, Hospital for Joint Diseases, New York University Medical Center, 301 East 17th Street, New York, NY 10003.Co-Director, Osteoporosis Center, Hospital for Joint Diseases, New York University Medical Center, 301 East 17th Street, New York, NY 10003.Search for more papers by this author Brian D. Golden MD, Corresponding Author Brian D. Golden MD Co-Director, Osteoporosis Center, Hospital for Joint Diseases, New York University Medical Center, 301 East 17th Street, New York, NY 10003.Co-Director, Osteoporosis Center, Hospital for Joint Diseases, New York University Medical Center, 301 East 17th Street, New York, NY 10003.Search for more papers by this author First published: 08 December 2005 https://doi.org/10.1002/art.1790110208Citations: 13AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646– 50. 2 Raisz L. G. Perspective: the osteoporosis revolution. Ann Intern Med 1997; 126: 458– 62. 3 Parfitt A. M. Quantum concept of bone remodeling and turnover: implications for pathogenesis of osteoporosis. Calcif Tissue Int 1979; 28: 1– 5. 4 Arlot M. E., Sornay-Rendu E., Garnero P., Vey-Marty B., Delmas P. D. Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res 1997; 12: 683– 90. 5 Heaney R. P., Recker R. R.. Saville P. D. Menopausal changes in bone remodeling. J Lab Clin Med 1978; 92: 964– 70. 6 Dempster D. W., Lindsay R. Pathogenesis of osteoporosis. Lancet 1993; 341: 797– 801. 7 The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 1389– 96. 8 Riggs B. L., Melton L. J. III. Involutional osteoporosis. N Engl J Med 1986; 314: 1676– 86. 9 Cummings S. R., Nevitt M. C., Browner W. S., Stone K., Fox K. M., Ensrud K. E., et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767– 73. 10 Slemenda C. W., Hui S. L., Longcope C., Wellman H., Johnston C. C. Jr. Predictors of bone mass in perimenopausal women. Ann Intern Med 1990; 112: 96– 101. 11 Cummings S. R., Black D. M., Nevitt M. C., Browner W., Cauley J., Ensrud K., et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341: 72– 5. 12 Wasnich R. D., Ross P. D., Heilbrun L. K., Vogel J. M. Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol 1985; 341: 72– 5. 13 Hui S. L., Slemenda C. W., Johnston C. C. Jr. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989; 111: 355– 61. 14 Hui S. L., Slemenda C. W., Johnston C. C. Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81: 1804– 9. 15 Johnston C. C. Jr., Slemenda C. W., Melton L. J. III. Clinical use of bone densitometry. N Engl J Med 1991; 324: 1105– 9. 16 Kanis J. A. Melton L. J. III., Christiansen C., Johnston C. C. Jr., Khaltaev N. Perspective: the diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137– 41. 17 Melton L. J. III., Chrischilles E. A., Cooper C., Lane A. W., Riggs B. L. Perspective: how many women have osteoporosis? J Bone Miner Res 1992; 7: 1005– 10. 18 Melton L. J. III. Osteoporosis: magnitude of the problem: worldwide and future. In: Osteoporosis: research advances and clinical applications: Fourth International Symposium on Osteoporosis., Washington, DC, June 4–7, 1997. Washington (DC): National Osteoporosis Foundation; 1997. p. 23. 19 Cooper C., Campion G., Melton L. J. III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2: 285– 9. 20 Lindsay R. Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol 1987; 156: 1347– 51. 21 Slemenda C. W. Can we improve peak bone mass? In: Osteoporosis: research advances and clinical applications: Fourth International Symposium on Osteoporosis. Washington, DC, June 4–7, 1997. Washington (DC): National Osteoporosis Foundation; 1997. p. 32. 22 Ralston S. H. Controls on genetics of bone: theory and fact. In: Osteoporosis: research advances and clinical applications: Fourth International Symposium on Osteoporosis., Washington, DC, June 4–7, 1997. Washington (DC): National Osteoporosis Foundation; 1997. p. 24. 23 Sainz J., van Tornot J. M., Loro M. L., Sayre J., Roe T. F., Gilsanz V. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med 1997; 337: 77– 82. 24 Johnston C. C. Jr., Miller J. Z., Slemenda C. W., Reister T. K., Hui S., Christian J. C., et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992; 327: 82– 7. 25 NIH Consensus Development Panel on Optimum Calcium Intake. Optimum calcium intake. JAMA 1994; 272: 1942– 8. 26 Riggs B. L., Melton L. J. III The prevention and treatment of osteoporosis. N Engl J Med 1992; 327: 620– 7. 27 Wyshak G., Frisch R. E., Albright T. E., Albright N. L., Schiff I., Witschi J. Nonalcoholic carbonated beverage consumption and bone fractures among women former college students. J Orthop Res 1989; 7: 91– 9. 28 Aloia J. F., Vaswani A., Yeh J. K., Ross P. L., Flaster E., Dilmanian F. A. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994; 120: 97– 103. 29 Simkin A., Ayalon J., Leichter I. Increased trabecular bone density due to bone-loading exercises in postmenopausal osteoporotic women. Calcif Tissue Int 1987; 40: 59– 63. 30 Dalsky G. P., Stocke K. S., Ehsani A. A., Slatopolosky E., Lee W. C., Birge S. J. Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med 1988; 108: 824– 8. 31 Nelson M. E., Fiatarone M. A., Morganti C. M., Trice I., Greenberg R. A., Evans W. J. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. JAMA 1994; 272: 1909– 14. 32 Albright F., Smith P. H., Richardson A. M. Postmenopausal osteoporosis. JAMA 1941; 116: 2465– 74. 33 Lindsay R., Aitken J. M., Anderson J. B., Hart D. M., Mac-Donald E. B., Clarke A. C. Long-term prevention of postmenopausal osteoporosis by estrogen. Lancet 1976; l: 1038– 41. 34 Lindsay R. Prevention of spinal osteoporosis in oophorectomized women. Lancet 1980; 2: 1151– 4. 35 Recker R. R., Saville P. D., Heaney R. P. Effects of oestrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977; 87: 649– 55. 36 Lindsay R., Hart D. M., MacLean A., Clark A. C., Kraszowski A., Garwood J. Bone response to termination of oestrogen treatment. Lancet 1978; 1: 1323– 7. 37 Christiansen C., Christensen M. S., Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogedgestagen replacement therapy. Lancet 1981; 1: 459– 61. 38 Felson D. T., Zhang Y., Hannan M. T., Kiel D. P., Wilson P. W. F., Anderson J. J. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141– 6. 39 Weiss N. A., Ure C. L., Ballard J. H., Williams A. R., Daling J. R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195– 8. 40 Cauley J. A., Seeley D. G., Ensrud K., Ettinger B., Black D., Cummings S. R. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122: 9– 16. 41 Maxim P., Ettinger B., Spitalny G. M. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995; 5: 23– 9. 42 Ettinger B., Genant H. K., Cann C. E. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319– 24. 43 Belchetz P. E. Hormonal treatment of postmenopausal women. N Engl J Med 1994; 330: 1062– 71. 44 Grodstein F., Stampfer M. J., Colditz G. A., Willett W. C., Manson J. E., Joffe M., et al. Postmenopausal hormone therapy and mortality. N Ehgl J Med 1997; 336: 1769– 75. 45 Stampfer M. J., Colditz G. A., Willett W. C., Manson J. E., Rosner B., Speizer F. E., et al. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991; 325: 756– 62. 46 Tang M. X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429– 32. 47 Colditz G. A., Hankinson S. E., Hunter D. J., Willett W. C., Manson J. E., Stampfer M. J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589– 93. 48 Speroff L., Rowan J., Symons J., Genant H., Wilborn W. The comparative effect on bone density., endometrium, and lipids of continuous hormones as replacement therapy (CHART study): a randomized controlled trial. JAMA 1996; 276: 1397– 403. 49 Steinberg K. K., Thacker S. B., Smith S. J., Stroup D. F., Zack M. M., Flanders W. D., et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985– 90. 50 Dupont W. D., Page D. L. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67– 72. 51 Watts N. B. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 1994; 20: 717– 34. 52 Delmas P. D., Meunier P. J. The management of Paget's disease of bone. N Engl J Med 1997; 336: 558– 66. 53 Murakami H., Takahashi N., Sasaki T., Udagawa N., Tanaka S., Nakamura I., et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995; 17: 137– 44. 54 Reginster J. Y., Deroisy R., Denis D., Collette J., Lecart M. P., Sarlet N., et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989; 79: 1469– 71. 55 Hosking D. J., McClung M. R., Ravin P., Wasnich R. D., Thompson D. E., Daley M. S., et al, for the EPIC Study Group. Alendronate in the prevention of osteoporosis: EPIC study two-year results. J Bone Miner Res 1996; 11 suppl 1: S133. 56 Liberman U. A., Weiss S. R., Bröll J., Minne H. W., Quan H., Bell N. H., et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437– 43. 57 Mortensen L., Bekker P., Ouweland F., Horowitz Z., Rupich R. Digennaro J., et al. Prevention of early postmenopausal bone loss by risedronate [abstract]. J Bone Miner Res 1995; 10: S140. 58 Steiniche T., Hasling C., Charles P., Eriksen E. F., Moskilde L., Melsen F. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 1989; 10: 313– 20. 59 Heaney R. P. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994; 9: 1515– 23. 60 Christiansen C., Riis B. J. 17B-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836– 41. 61 Lindsay R., Tohme J. F. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990; 76: 290– 5. 62 Lufkin E. G., Wahner H. W., O'Fallon W. M., Hodgson S. F., Kotowicz M. A., Lane A. W., et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1– 9. 63 Lufkin E. G., Riggs B. L. Three-year follow-up on effects of transdermal estrogen [letter]. Ann Intern Med 1996; 125: 77. 64 Quigley M. E., Martin C. L., Bunnier A. M., Brooks P. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987; 156: 1516– 23. 65 Storm T., Thamsborg G., Steiniche T., Genant H. K., Sorensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265– 71. 66 Watts N. B., Harris S. T., Genant H. K., Wasnich R. D., Miller P. D., Jackson R. D., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73– 9. 67 Harris S. T., Watts N. B., Jackson R. D., Genant H. K., Wasnich R. D., Ross P., et al. Four-year study of intermittent etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557– 67. 68 Marcus R. Cyclic etidronate: has the rose lost its bloom? Am J Med 1993; 95: 555– 6. 69 Black D. M., Cummings S. R., Karpf D. B., Cauler J. A., Thompson D. E., Nevitt M. C., et al, for the Fracture Intervention Trial Research Group. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535– 41. 70 DeGroen P. C., Lubbe D. F., Hirsch L. J., Dafotis A., Stephenson W., Freedholm D., et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016– 21. 71 Reginster J. Y., Jeugmans-Huynen A. M., Albert A., Denis D., Deroisy R., Lecart M. P., et al. Biological and clinical assessment of a new bisphosphonate., (chloro-4 phenyl) thiomethylene bisphosphonate., in the treatment of Paget's disease of bone. Bone 1988; 9: 349– 54. 72 Reginster J. Y. L. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 1992; 13: 351– 4. 73 Chestnut C. H. III. Tiludronate: development as an osteoporosis therapy. Bone 1995; 17 Suppl: 517S– 9S. 74 Skelid (tiludronate disodium) prescribing information. New York Sanofi Pharmaceuticals., Inc. 75 Giannini S., D'Angelo A., Malvasi L., Castrignano R., Pati T., Tronca R., et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 1993; 14: 137– 41. 76 Thiebaud D., Burckhardt P., Melchior J., Eckert P., Jacquet A. F., Schnyder P., et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994; 4: 76– 83. 77 Delmas P. D., Balena R., Confravreux E., Hardouin C., Hardy P., Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer. J Clin Oncol 1997; 15: 955– 62. 78 Wallach S. Calcitonin: history and prospects—a personal view. Semin Arthritis Rheum 1994; 23: 25– 60. 79 Wallach S. Management of osteoporosis. Hosp Pract 1978; 13: 91– 8. 80 Siminoski K., Josse R. G. Calcitonin in the treatment of osteoporosis. Can Med Assoc J 1996; 155: 962– 5. 81 Miacalcin package insert. Ast Hanover (NJ): Sandoz Pharmaceuticals Corporation. 82 Lyritis G. P., Tsakalakos N., Magiasis B., Karachalios T., Yiatzides A., Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a doubleblind placebo-controlled clinical study. Calcif Tissue Int 1991; 49: 369– 72. 83 Overgaard K. Nasal salmon calcitonin in osteoporosis. Calcif Tissue Int 1994; 55: 79– 81. 84 Overgaard K., Hansen M. A., Jensen S. B., Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a doseresponse study. BMJ 1992; 305: 556– 61. 85 Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994; 55: 82– 6. 86 Reginster J. Y., Meunnans L., Deroisy R., Jupsin I., Biquet I., Albert A., et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994; 24: 565– 9. 87 Rochefort H. Mechanism of action of high-affinity antiestrogens. Am J Clin Oncol 1991;14 Suppl 2: S1– 4. 88 Webster N. J. G., Green S., Jin J. R., Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 1988; 54: 199– 207. 89 Grainger D. J., Metcalfe J. C. Tamoxifen: teaching an old drug new tricks? Nat Med 1996; 2: 381– 5. 90 Love R. R., Mazess R. B., Barden H. S., Epstein S., Newcomb P. A., Jordan V. C., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852– 6. 91 Powles T. J., Hickish T., Kanis J. A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78– 84. 92 Grey A. B., Stapleton J. P., Evans M. C., Tatnell M. A., Ames R. W., Reid I. R. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995; 99: 636– 41. 93 Kenny A. M., Prestwood K. M., Pilbeam C. C., Raisz L. G. The short-term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 1995; 80: 3287– 91. 94 Neven P., DeMuylder X., van Belle Y. Tamoxifeninduced endometrial polyp [letter]. N Engl J Med 1997; 336: 1389– 90. 95 Ismail S. M. Effects of tamoxifen on uterus [letter]. Lancet 1994; 344: 622– 3. 96 Black L. J., Sato M., Rowley E. R., Magee D. E., Bekele A., Williams D. C., et al. Raloxifene (LY139481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93: 63– 9. 97 Ke H. Z., Simmons H. A., Pirie C. M., Crawford D. T., Thompson D. D. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 1995; 136: 2435– 41. 98 Chen H. K., Ke H. Z., Jee W. S. S., Ma Y. F., Pirie C. M., Simmons H. A., et al. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy x-ray absorptiometric and histomorphometric study. J Bone Miner Res 1995; 10: 1256– 62. 99 Eppenberger U., Wosikowski K., Kung W. Pharmacologic and biologic properties of droloxifene., a new antiestrogen. Am J Clin Oncol 1991; 14 Suppl 2: S5– 14. 100 Johnston C. C. Jr. Clinical applications of selective estrogen receptor modulators (SERMS) in the management of postmenopausal women (satellite symposium). In: Osteoporosis: research advances and clinical applications: Fourth International Symposium on Osteoporosis., Washington, DC, June 47, 1997. Washington (DC): National Osteoporosis Foundation; 1997. p. 20. 101 Dempster D. W., Cosman F., Parisien M., Shen V., Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14: 690– 709. 102 Reeve J., Arlot M. E., Bradbeer J. N., Hesp R., McAlly E., Meunier P. J., et al. Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporos Int 1993; Suppl 1: S199– 203. 103 Lane N. E., Thompson J. M., Strewler G. J., Kinney J. H. Intermittent treatment with human parathyroid hormone (hPTH [1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J Bone Miner Res 1995; 10: 1470– 7. 104 Reeve J., Meunier P. J., Parsons J. A., Bernat M., Bijoet O. L. M., Courpron P., et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980; 280: 1340– 4. 105 Lindsay R., Nieves J., Henneman E., Shen V., Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone (1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993; 77: 1535– 9. 106 Finkelstein J. S., Klibanski A., Schaefer E. H., Hornstein M. D., Schiff I., Neer R. M. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994; 331: 1618– 23. 107 Kleerekoper M., Mendlovic D. B. Sodium fluoride therapy of postmenopausal osteoporosis. Endocr Rev 1993; 14: 312– 23. 108 Riggs B. L., Hodgson S. F., O'Fallon W. M., Chao E. Y. S., Wahner H. W., Muhs J. M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Ehgl J Med 1990; 322: 802– 9. 109 Kleerekoper M., Peterson E. L., Nelson D. A., Phillips E., Schork M. A., Tilley B. C., et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991; 1: 155– 61. 110 Pak C. Y. C., Sakhaee K., Adams-Huet B., Piziak V., Peterson R. D., Poindexter J. R. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401– 8. 111 Mundy G. R. Osteoporosis into the year 2010. Br J Obstet Gynecol 1996;103 Suppl 13: 32– 8. 112 Kimmel D. B., Slovik D. M., Lane N. E. Current and investigational approaches for reversing established osteoporosis. Rheum Dis Clin North Am 1994; 20: 735– 58. Citing Literature Volume11, Issue2April 1998Pages 124-134 ReferencesRelatedInformation" @default.
• W2085764274 created "2016-06-24" @default.
• W2085764274 creator A5090724029 @default.
• W2085764274 date "1998-04-01" @default.
• W2085764274 modified "2023-10-16" @default.
• W2085764274 title "The prevention and treatment of osteoporosis" @default.
• W2085764274 cites W1561293749 @default.
• W2085764274 cites W1963785335 @default.
• W2085764274 cites W1964321896 @default.
• W2085764274 cites W1966327760 @default.
• W2085764274 cites W1967288745 @default.
• W2085764274 cites W1967908649 @default.
• W2085764274 cites W1968418396 @default.
• W2085764274 cites W1970422815 @default.
• W2085764274 cites W1971658757 @default.
• W2085764274 cites W1979353935 @default.
• W2085764274 cites W1981476886 @default.
• W2085764274 cites W1982376401 @default.
• W2085764274 cites W1982942836 @default.
• W2085764274 cites W1985184665 @default.
• W2085764274 cites W1986445986 @default.
• W2085764274 cites W1988797394 @default.
• W2085764274 cites W1999190022 @default.
• W2085764274 cites W1999382396 @default.
• W2085764274 cites W2004236425 @default.
• W2085764274 cites W2008039212 @default.
• W2085764274 cites W2010020452 @default.
• W2085764274 cites W2013079995 @default.
• W2085764274 cites W2015178646 @default.
• W2085764274 cites W2025733870 @default.
• W2085764274 cites W2029475329 @default.
• W2085764274 cites W2031570803 @default.
• W2085764274 cites W2033633524 @default.
• W2085764274 cites W2034145256 @default.
• W2085764274 cites W2035593552 @default.
• W2085764274 cites W2038830087 @default.
• W2085764274 cites W2040645421 @default.
• W2085764274 cites W2046529319 @default.
• W2085764274 cites W2046983302 @default.
• W2085764274 cites W2049394900 @default.
• W2085764274 cites W2049760032 @default.
• W2085764274 cites W2052533937 @default.
• W2085764274 cites W2052759041 @default.
• W2085764274 cites W2053194047 @default.
• W2085764274 cites W2054670558 @default.
• W2085764274 cites W2062229770 @default.
• W2085764274 cites W2066226218 @default.
• W2085764274 cites W2066739013 @default.
• W2085764274 cites W2070815981 @default.
• W2085764274 cites W2073024058 @default.
• W2085764274 cites W2073081018 @default.
• W2085764274 cites W2073621968 @default.
• W2085764274 cites W2075572846 @default.
• W2085764274 cites W2075992155 @default.
• W2085764274 cites W2077163152 @default.
• W2085764274 cites W2077310525 @default.
• W2085764274 cites W2078406992 @default.
• W2085764274 cites W2087337970 @default.
• W2085764274 cites W2090283784 @default.
• W2085764274 cites W2092791248 @default.
• W2085764274 cites W2093749501 @default.
• W2085764274 cites W2094307839 @default.
• W2085764274 cites W2094937528 @default.
• W2085764274 cites W2098533587 @default.
• W2085764274 cites W2098644676 @default.
• W2085764274 cites W2099116126 @default.
• W2085764274 cites W2114358979 @default.
• W2085764274 cites W2117823510 @default.
• W2085764274 cites W2117828778 @default.
• W2085764274 cites W2121436732 @default.
• W2085764274 cites W2125725130 @default.
• W2085764274 cites W2127677509 @default.
• W2085764274 cites W2149500256 @default.
• W2085764274 cites W2151649765 @default.
• W2085764274 cites W2153009489 @default.
• W2085764274 cites W2163445297 @default.
• W2085764274 cites W2164840368 @default.
• W2085764274 cites W2165045342 @default.
• W2085764274 cites W2313999721 @default.
• W2085764274 cites W2321227665 @default.
• W2085764274 cites W2323830513 @default.
• W2085764274 cites W2323923429 @default.
• W2085764274 cites W2325502017 @default.
• W2085764274 cites W2326201416 @default.
• W2085764274 cites W2336517627 @default.
• W2085764274 cites W2336678594 @default.
• W2085764274 cites W2337197041 @default.
• W2085764274 cites W2337884406 @default.
• W2085764274 cites W2337977161 @default.
• W2085764274 cites W2338901418 @default.
• W2085764274 cites W2340559658 @default.
• W2085764274 cites W2414769109 @default.
• W2085764274 cites W2428059568 @default.
• W2085764274 cites W2429148866 @default.
• W2085764274 cites W2599867508 @default.
• W2085764274 cites W2607238143 @default.
• W2085764274 cites W2972867833 @default.
• W2085764274 cites W4211065807 @default.

• next